Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects

Setsuo Hasegawa, Kazunori Saito, Michiko Kainuma, Kazuhiro Matsuki, Yoshinobu Yasuda, Seong Ryul Kim Kim, Naoko Shimofurutani, Eiichi Saitoh

研究成果: Article

抄録

Cilostazol 20% powder is an orally disintegrated formulation that was newly developed for easier swallowing by patients with swallowing disorders that make it difficult for them to take cilostazol tablets with water. The buccal absorption of cilostazol 20% powder was evaluated in an open-label, randomized, 2-treatment, 2-period crossover study in 14 healthy adult male subjects by comparison of when cilostazol 20% powder was disintegrated in the mouth and swallowed and when it was held in the mouth for 3 minutes without swallowing and then spit out. Although the concentration of cilostazol recovered in the saliva and rinsing water collected from non-swallowing administration was 92.04%, being lower than the criteria of 95%, the mean ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration were respectively 0.05% and 0.08%, both being lower than 5%, the judgment criteria for buccal absorption. As the ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration met the judgment criteria, it was concluded that buccal absorption of cilostazol does not contribute to bioavailability when cilostazol 20% powder is orally administrated.

元の言語English
ページ(範囲)73-79
ページ数7
ジャーナルJapanese Pharmacology and Therapeutics
35
発行部数1
出版物ステータスPublished - 01-12-2007

Fingerprint

Powders
Deglutition
Mouth
Water
Deglutition Disorders
Oral Mucosal Absorption
cilostazol
Saliva
Cross-Over Studies
Biological Availability
Tablets

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Hasegawa, S., Saito, K., Kainuma, M., Matsuki, K., Yasuda, Y., Kim, S. R. K., ... Saitoh, E. (2007). Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects. Japanese Pharmacology and Therapeutics, 35(1), 73-79.
Hasegawa, Setsuo ; Saito, Kazunori ; Kainuma, Michiko ; Matsuki, Kazuhiro ; Yasuda, Yoshinobu ; Kim, Seong Ryul Kim ; Shimofurutani, Naoko ; Saitoh, Eiichi. / Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects. :: Japanese Pharmacology and Therapeutics. 2007 ; 巻 35, 番号 1. pp. 73-79.
@article{71fae298bd1146aaad01ba62b22107dc,
title = "Assessment of buccal absorption of cilostazol 20{\%} powder in healthy adult male subjects",
abstract = "Cilostazol 20{\%} powder is an orally disintegrated formulation that was newly developed for easier swallowing by patients with swallowing disorders that make it difficult for them to take cilostazol tablets with water. The buccal absorption of cilostazol 20{\%} powder was evaluated in an open-label, randomized, 2-treatment, 2-period crossover study in 14 healthy adult male subjects by comparison of when cilostazol 20{\%} powder was disintegrated in the mouth and swallowed and when it was held in the mouth for 3 minutes without swallowing and then spit out. Although the concentration of cilostazol recovered in the saliva and rinsing water collected from non-swallowing administration was 92.04{\%}, being lower than the criteria of 95{\%}, the mean ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration were respectively 0.05{\%} and 0.08{\%}, both being lower than 5{\%}, the judgment criteria for buccal absorption. As the ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration met the judgment criteria, it was concluded that buccal absorption of cilostazol does not contribute to bioavailability when cilostazol 20{\%} powder is orally administrated.",
author = "Setsuo Hasegawa and Kazunori Saito and Michiko Kainuma and Kazuhiro Matsuki and Yoshinobu Yasuda and Kim, {Seong Ryul Kim} and Naoko Shimofurutani and Eiichi Saitoh",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "35",
pages = "73--79",
journal = "Japanese Pharmacology and Therapeutics",
issn = "0386-3603",
publisher = "Life Science Publishing Co. Ltd",
number = "1",

}

Hasegawa, S, Saito, K, Kainuma, M, Matsuki, K, Yasuda, Y, Kim, SRK, Shimofurutani, N & Saitoh, E 2007, 'Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects', Japanese Pharmacology and Therapeutics, 巻. 35, 番号 1, pp. 73-79.

Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects. / Hasegawa, Setsuo; Saito, Kazunori; Kainuma, Michiko; Matsuki, Kazuhiro; Yasuda, Yoshinobu; Kim, Seong Ryul Kim; Shimofurutani, Naoko; Saitoh, Eiichi.

:: Japanese Pharmacology and Therapeutics, 巻 35, 番号 1, 01.12.2007, p. 73-79.

研究成果: Article

TY - JOUR

T1 - Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects

AU - Hasegawa, Setsuo

AU - Saito, Kazunori

AU - Kainuma, Michiko

AU - Matsuki, Kazuhiro

AU - Yasuda, Yoshinobu

AU - Kim, Seong Ryul Kim

AU - Shimofurutani, Naoko

AU - Saitoh, Eiichi

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Cilostazol 20% powder is an orally disintegrated formulation that was newly developed for easier swallowing by patients with swallowing disorders that make it difficult for them to take cilostazol tablets with water. The buccal absorption of cilostazol 20% powder was evaluated in an open-label, randomized, 2-treatment, 2-period crossover study in 14 healthy adult male subjects by comparison of when cilostazol 20% powder was disintegrated in the mouth and swallowed and when it was held in the mouth for 3 minutes without swallowing and then spit out. Although the concentration of cilostazol recovered in the saliva and rinsing water collected from non-swallowing administration was 92.04%, being lower than the criteria of 95%, the mean ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration were respectively 0.05% and 0.08%, both being lower than 5%, the judgment criteria for buccal absorption. As the ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration met the judgment criteria, it was concluded that buccal absorption of cilostazol does not contribute to bioavailability when cilostazol 20% powder is orally administrated.

AB - Cilostazol 20% powder is an orally disintegrated formulation that was newly developed for easier swallowing by patients with swallowing disorders that make it difficult for them to take cilostazol tablets with water. The buccal absorption of cilostazol 20% powder was evaluated in an open-label, randomized, 2-treatment, 2-period crossover study in 14 healthy adult male subjects by comparison of when cilostazol 20% powder was disintegrated in the mouth and swallowed and when it was held in the mouth for 3 minutes without swallowing and then spit out. Although the concentration of cilostazol recovered in the saliva and rinsing water collected from non-swallowing administration was 92.04%, being lower than the criteria of 95%, the mean ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration were respectively 0.05% and 0.08%, both being lower than 5%, the judgment criteria for buccal absorption. As the ratios of the AUC60h and Cmax for non-swallowing administration to those for swallowing administration met the judgment criteria, it was concluded that buccal absorption of cilostazol does not contribute to bioavailability when cilostazol 20% powder is orally administrated.

UR - http://www.scopus.com/inward/record.url?scp=56249140492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249140492&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:56249140492

VL - 35

SP - 73

EP - 79

JO - Japanese Pharmacology and Therapeutics

JF - Japanese Pharmacology and Therapeutics

SN - 0386-3603

IS - 1

ER -

Hasegawa S, Saito K, Kainuma M, Matsuki K, Yasuda Y, Kim SRK その他. Assessment of buccal absorption of cilostazol 20% powder in healthy adult male subjects. Japanese Pharmacology and Therapeutics. 2007 12 1;35(1):73-79.